Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer

Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer

The overwhelming success of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients has opened a discussion among medical practitioners and the lay public on the real possibility of pregnancy and conception in females and males with CML. In the past 10 years this subject h...

Full description

Bibliographic Details
Main Authors:	Elisabetta Abruzzese, Stefano Aureli, Francesco Bondanini, Mariavita Ciccarone, Elisabetta Cortis, Antonello Di Paolo, Cristina Fabiani, Sara Galimberti, Michele Malagola, Alessandra Malato, Bruno Martino, Malgorzata Monika Trawinska, Domenico Russo, Paolo de Fabritiis
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Journal of Clinical Medicine
Subjects:	CML pregnancy placental transfer TKIs PEG-IFN conception
Online Access:	https://www.mdpi.com/2077-0383/11/7/1801

Similar Items

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2
by: Sara Galimberti, et al.
Published: (2020-09-01)

Acute Basophilic Leukemia Arising from Chronic Myeloid Leukemia with +8, I(17q)(q10) and der(22)t(9;22) After Imatinib Therapy
by: Shan P, et al.
Published: (2023-09-01)

SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection
by: Elisabetta Abruzzese, et al.
Published: (2020-04-01)

The Downregulation of Both Giant HERCs, <i>HERC1</i> and <i>HERC2</i>, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation
by: Muhammad Shahzad Ali, et al.
Published: (2022-01-01)

HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases
by: Stefano Fiori, et al.
Published: (2021-02-01)

Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response
by: Shifang Wang, et al.
Published: (2020-07-01)

CD26/DPP-4 in Chronic Myeloid Leukemia
by: Anna Sicuranza, et al.
Published: (2022-02-01)

Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities
by: Lukasz Komorowski, et al.
Published: (2020-08-01)

NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
by: Gianfranco Catalano, et al.
Published: (2020-10-01)

PREDICTORS OF SUSTAINED RESPONSE TO INTERFERON-BASED THERAPY IN CHRONIC HEPATITIS B
by: Deian Jelev, et al.
Published: (2011-10-01)

Interferon and interferon-stimulated genes in HBV treatment
by: Qirong Li, et al.
Published: (2022-12-01)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
by: Michele Massimino, et al.
Published: (2021-06-01)

Adverse Effects of Two Different Peginterferon Molecules with Ribavirin Combination Therapy Used To Treat Chronic Hepatitis C
by: Saygın NAYMAN ALPAT, et al.
Published: (2008-06-01)

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib
by: Hayder M. Al-kuraishy, et al.
Published: (2018-01-01)

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea
by: Junghoon Shin, et al.
Published: (2018-05-01)

Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib
by: Sabina Russo, et al.
Published: (2015-10-01)

Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts
by: Lin Kung-Hung, et al.
Published: (2012-01-01)

Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B
by: Mangano Carmelo, et al.
Published: (2011-01-01)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
by: Alexander Yakobson, et al.
Published: (2023-09-01)

Evaluation of Electrolytes Disturbances in Iraqi Chronic Myeloid Leukemia Patients treated with Nilotinib with Monitoring of Response by FISH Study
by: Baghdad Science Journal
Published: (2015-03-01)

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
by: Ali Ibrahim, et al.
Published: (2022-05-01)

Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
by: Paulina Kwaśnik, et al.
Published: (2021-07-01)

Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies
by: Salma Younes, et al.
Published: (2023-12-01)

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience
by: Beatriz Felicio Ribeiro, et al.
Published: (2015-08-01)

Tailored CML Treatment in Indonesia, Let’s See More
by: Shinta Oktya Wardhani
Published: (2023-11-01)

The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population
by: Massimiliano Bonifacio, et al.
Published: (2021-09-01)

Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice
by: Luisa Cavalletto, et al.
Published: (2008-01-01)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
by: Hao Zhang, et al.
Published: (2022-03-01)

Are Successful Pregnancies an Achievable Goal in Patients with Chronic Myeloid Leukaemia?
by: Zhanet Grudeva-Popova, et al.
Published: (2019-08-01)

PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO PEGYLATED INTERFERON ALPHA (PEG-IFN α) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1.
by: Krasimir Antonov, et al.
Published: (2011-12-01)

Hodgkin’s lymphoma in a man with dilated cardiomyopathy and paraneoplastic ataxia: a therapeutical challenge
by: Elisabetta Abruzzese, et al.
Published: (2017-06-01)

Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro
by: Louisa Pechlivani, et al.
Published: (2024-03-01)

POSSIBILITIES OF HEPATITIS C ANTIVIRAL TREATMENT IN LIVER TRANSPLANT RECIPIENTS
by: V. E. Syutkin, et al.
Published: (2011-06-01)

Peg3 Deficiency Results in Sexually Dimorphic Losses and Gains in the Normal Repertoire of Placental Hormones
by: Simon J. Tunster, et al.
Published: (2018-09-01)

Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)
by: Elisabetta Abruzzese, et al.
Published: (2023-08-01)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
by: Diego Centonze, et al.
Published: (2021-04-01)

Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment
by: Malgorzata Sidorkiewicz, et al.
Published: (2020-06-01)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
by: Yan L, et al.
Published: (2018-10-01)

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
by: Trinks J, et al.
Published: (2017-03-01)